Anzeige
Meldung des Tages: Die Lizenz, über die niemand spricht, und warum Wettbewerber keine bekommen

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Medikamente Land:  Frankreich
71,08 €
-1,42 €
-1,96%
02.10.26
Depot/Watchlist
Marktkapitalisierung *
87,03 Mrd. €
Streubesitz
43,71%
KGV
8,53
Dividende
3,92 EUR
Dividendenrendite
5,29%
Nachhaltigkeits-Score
69 %
Index-Zuordnung
Euro Stoxx 50
Weiter abwärts? Short handeln - Jetzt mit Faktor 2,00: JY7L5Q
Werbung

Ad-hocs

01.10.26 - GlobeNewswire
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple nex t-​generation, long-​acting immunology antibodies
14.09.26 - GlobeNewswire
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and  Cheplaphar m to create new strategic partnership i n mature medicines
04.08.26 - GlobeNewswire
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
30.07.26 - GlobeNewswire
Press Release: Sanofi’s half-year financial report for 2026
Sanofi’s half-year financial report for 2026
30.07.26 - GlobeNewswire
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
Q2 2026: double-​digit sales growth and strong business EPS growth; 2026 guidance upgraded
21.07.26 - GlobeNewswire
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi evolves its Executive Committee to support its next strategic chapter
10.07.26 - GlobeNewswire
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
01.07.26 - GlobeNewswire
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results
30.06.26 - GlobeNewswire
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-​onset Pompe disease phase 3 study
25.06.26 - GlobeNewswire
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations
23.06.26 - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-​immune modulation to help address the underlying causes ...
23.06.26 - GlobeNewswire
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-​targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a ...
22.06.26 - GlobeNewswire
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi a ppoints Paulo Fontoura as Global  Head of  R&D
19.06.26 - GlobeNewswire
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
13.06.26 - GlobeNewswire
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi’s Tzield approved in the US as the first disease-​modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
10.06.26 - GlobeNewswire
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
08.06.26 - GlobeNewswire
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa administered via the CirCLIQ ® OBI offers a ...
04.06.26 - GlobeNewswire
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan
28.05.26 - GlobeNewswire
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review ...
18.05.26 - GlobeNewswire
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD  
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-​of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-​to-head ...

Newssuche

Videos

newspaper
28.09.26 +35,48%
Technical Trading Montags Schwäche nutzen
Gold Short Typ: Turbo Open End WKN: BD732R Hebel:43,25 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Weitere Videos ❯

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren

Wir sind wieder bei den Zertifikate Awards dabei!

Auch in diesem Jahr nimmt ARIVA.DE wieder an den Zertifikate Awards teil. Stimme jetzt für deine Favoriten ab — deine Stimme zählt!

✈️
Zu gewinnen
Eine Reise nach Berlin

Unter allen Teilnehmerinnen und Teilnehmern wird mit etwas Glück eine Reise nach Berlin verlost. Danke, dass du dabei bist!

Jetzt abstimmen →